News and Media
News and Media
Temporary transfer of Valerio Therapeutics shares to the Penalty Bench from 16 May 2025
May 22, 2025
Valerio Therapeutics announces the postponement of its 2024 annual results due to accounting issues related to its U.S. subsidiary.
May 22, 2025
Valerio Therapeutics announces governance changes following the board meeting of February 20, 2025
March 7, 2025
KEPLER CHEVREUX liquidity contract termination, February 27th, 2025
February 27, 2025
Strategic refocus, February 3rd, 2025
February 3, 2025
Meeting of the Board of Directors of Valerio Therapeutics S.A. on November 13, 2024
November 15, 2024
Valerio Therapeutics Acquires Emglev Therapeutics, a Single-domain Antibody-based Therapeutics Company
September 30, 2024
Valerio Therapeutics Reports its Half-Year 2024 Financial Results and Provides an Update on its Activities
September 30, 2024
Half-year liquidity contract statement for Valerio Therapeutics
September 29, 2024
Valerio Therapeutics: report on the Combined General Meeting of June 5, 2024
June 5, 2024
Valerio Therapeutics Provides Clinical Development Update on Its Phase 1/2 VIO-01 Clinical Trial
May 22, 2024
Publication of the 2023 Annual Report
April 30, 2024
Valerio Therapeutics Reports Full Year 2023 Financial Results and Provides Clinical Development Updates
April 30, 2024
Valerio Therapeutics announces a capital reduction motivated by losses by reducing the nominal value of the Company’s shares
February 5, 2024
Half-year liquidity contract statement for Valerio Therapeutics
January 25, 2024
Press Release Signup
Subscribe to receive our Press Releases when they come out.
